Cargando…

Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions

For differentiated thyroid cancer (DTC), systemic therapy with radioactive iodine (RAI) is utilized for radiosensitive disease, while for radioiodine refractory (RAIR) disease, current standard of care is treatment with multikinase tyrosine kinase inhibitors (TKI). For BRAF-mutant DTC or anaplastic...

Descripción completa

Detalles Bibliográficos
Autores principales: Porter, Ashleigh, Wong, Deborah J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868523/
https://www.ncbi.nlm.nih.gov/pubmed/33569345
http://dx.doi.org/10.3389/fonc.2020.592202
_version_ 1783648467442204672
author Porter, Ashleigh
Wong, Deborah J.
author_facet Porter, Ashleigh
Wong, Deborah J.
author_sort Porter, Ashleigh
collection PubMed
description For differentiated thyroid cancer (DTC), systemic therapy with radioactive iodine (RAI) is utilized for radiosensitive disease, while for radioiodine refractory (RAIR) disease, current standard of care is treatment with multikinase tyrosine kinase inhibitors (TKI). For BRAF-mutant DTC or anaplastic thyroid cancer (ATC), treatment with inhibitors targeting BRAF and MEK are important advances. RET-inhibitors for RET-mutated medullary thyroid cancer (MTC) recently have been FDA-approved for metastatic disease. Nevertheless, treatment of thyroid cancer resistant to current systemic therapies remains an important area of need. Resistance mechanisms are being elucidated, and novel therapies including combinations of BRAF and MEK inhibitors with RAI or other targeted therapies or TKIs combined with checkpoint inhibition are current areas of exploration.
format Online
Article
Text
id pubmed-7868523
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78685232021-02-09 Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions Porter, Ashleigh Wong, Deborah J. Front Oncol Oncology For differentiated thyroid cancer (DTC), systemic therapy with radioactive iodine (RAI) is utilized for radiosensitive disease, while for radioiodine refractory (RAIR) disease, current standard of care is treatment with multikinase tyrosine kinase inhibitors (TKI). For BRAF-mutant DTC or anaplastic thyroid cancer (ATC), treatment with inhibitors targeting BRAF and MEK are important advances. RET-inhibitors for RET-mutated medullary thyroid cancer (MTC) recently have been FDA-approved for metastatic disease. Nevertheless, treatment of thyroid cancer resistant to current systemic therapies remains an important area of need. Resistance mechanisms are being elucidated, and novel therapies including combinations of BRAF and MEK inhibitors with RAI or other targeted therapies or TKIs combined with checkpoint inhibition are current areas of exploration. Frontiers Media S.A. 2021-01-25 /pmc/articles/PMC7868523/ /pubmed/33569345 http://dx.doi.org/10.3389/fonc.2020.592202 Text en Copyright © 2021 Porter and Wong http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Porter, Ashleigh
Wong, Deborah J.
Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions
title Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions
title_full Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions
title_fullStr Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions
title_full_unstemmed Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions
title_short Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions
title_sort perspectives on the treatment of advanced thyroid cancer: approved therapies, resistance mechanisms, and future directions
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868523/
https://www.ncbi.nlm.nih.gov/pubmed/33569345
http://dx.doi.org/10.3389/fonc.2020.592202
work_keys_str_mv AT porterashleigh perspectivesonthetreatmentofadvancedthyroidcancerapprovedtherapiesresistancemechanismsandfuturedirections
AT wongdeborahj perspectivesonthetreatmentofadvancedthyroidcancerapprovedtherapiesresistancemechanismsandfuturedirections